These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36817637)

  • 1. Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy.
    Miyakubo T; Mukai R; Matsumoto H; Morimoto M; Takahashi M; Nagai K; Nakamura K; Hoshino J; Akiyama H
    Clin Ophthalmol; 2023; 17():571-577. PubMed ID: 36817637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
    PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial.
    Silva R; Arias L; Nunes S; Farinha C; Coimbra R; Marques JP; Cachulo ML; Figueira J; Barreto P; Madeira MH; Pires I; Sousa JC; Distefano L; Rosa P; Carneiro Â; Vaz-Pereira S; Meireles A; Cabrera F; Bures A; Mendonça L; Fernandez-Vega-Sanz A; Barrão S; Koh A; Cheung CMG; Cunha-Vaz JG; Murta J;
    Ophthalmologica; 2022; 245(1):80-90. PubMed ID: 34348351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy.
    Vyas CH; Cheung CMG; Tan C; Chee C; Wong K; Jordan-Yu JMN; Wong TY; Tan A; Fenner B; Sim S; Teo KYC
    BMJ Open; 2021 Jul; 11(7):e050252. PubMed ID: 34266844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M; Matsumoto H; Mimura K; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
    Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
    Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.
    Marques JP; Farinha C; Costa MÂ; Ferrão Â; Nunes S; Silva R
    BMJ Open; 2017 Aug; 7(8):e015785. PubMed ID: 28851779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept.
    Xue Y; Qinhua C
    Front Med (Lausanne); 2022; 9():835255. PubMed ID: 35252267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population.
    Wolff B; Vasseur V; Cahuzac A; Coscas F; Castelnovo L; Favard C; Michel G; Français C; Salomon L; Mauget-Faÿsse M
    Ophthalmologica; 2018; 240(4):208-212. PubMed ID: 29804123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy.
    Weng HY; Huang TL; Chang PY; Wang JK
    BMC Pharmacol Toxicol; 2019 May; 20(1):29. PubMed ID: 31088543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Tamachi T; Kohno T; Yamamoto M; Hirayama K; Kyo A; Ueda N; Hirabayashi M; Shiraki K; Honda S
    Ophthalmol Ther; 2020 Dec; 9(4):1069-1082. PubMed ID: 33058069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Kume A; Iijima H
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S; Matsumiya W; Miki A; Honda S; Nakamura M
    Jpn J Ophthalmol; 2019 Sep; 63(5):389-395. PubMed ID: 31376050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.
    Lee WK; Iida T; Ogura Y; Chen SJ; Wong TY; Mitchell P; Cheung GCM; Zhang Z; Leal S; Ishibashi T;
    JAMA Ophthalmol; 2018 Jul; 136(7):786-793. PubMed ID: 29801063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
    Lai TY; Lee GK; Luk FO; Lam DS
    Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
    Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
    Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
    Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
    Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Polyp Regression on 2-year Outcomes of Intravitreal Aflibercept Injections: A Treat-and-Extend Regimen for Polypoidal Choroidal Vasculopathy.
    Morizane-Hosokawa M; Morizane Y; Kimura S; Shiode Y; Hirano M; Doi S; Toshima S; Hosogi M; Fujiwara A; Shiraga F
    Acta Med Okayama; 2018 Aug; 72(4):379-385. PubMed ID: 30140086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.